# An Open-Label, Dose Escalation Study to Evaluate the Safety and the Pharmacokinetics of Oral PRX-112

> **NCT02107846** · PHASE2 · COMPLETED · sponsor: **Protalix** · enrollment: 10 (actual)

## Conditions studied

- Gaucher Disease

## Interventions

- **DRUG:** PRX-112

## Key facts

- **NCT ID:** NCT02107846
- **Lead sponsor:** Protalix
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-04
- **Primary completion:** 2015-12
- **Final completion:** 2015-12
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2016-09-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02107846

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02107846, "An Open-Label, Dose Escalation Study to Evaluate the Safety and the Pharmacokinetics of Oral PRX-112". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02107846. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*